93P Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study

T Okusaka,M Kitano,M-H Chen,J-S Chen,V.S Ostwal,M.G Mcnamara,V Breder,M Petrova,G Buchschacher,N Rokutanda,J Xiong,G Cohen,D-Y Oh

doi:10.1016/j.annonc.2022.10.129

93P Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study

T Okusaka, M Kitano + Show 11 more

https://doi.org/10.1016/j.annonc.2022.10.129

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
Citations: 1

Affiliation: Wakayama Medical University, Taipei Veterans General Hospital, Chang Gung Memorial Hospital, Tata Memorial Hospital, The Christie NHS Foundation Trust, National Medical Research Center of Cardiology, Los Angeles Medical Center, Seoul National University

#Study Of First-line Durvalumab #Advanced Biliary Tract Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

TOPAZ-1 (NCT03875235) is a randomised, double-blind, global, Phase 3 study of first-line durvalumab (D) + gemcitabine and cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC). D + GemCis improved overall survival vs placebo (PBO) + GemCis, and is a potential new treatment option for advanced BTC (Oh et al. NEJM Evid 2022; https://doi.org/10.1056/EVIDoa2200015). In BTC, disease status at baseline may impact response to treatment.

Full Text